Company

NeuroSearch A/S

As of the edition of 20 October 2026, NeuroSearch A/S runs 3 drugs; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

NeuroSearch A/S was acquired.

  • NeuroSearch A/S: acquired

Drugs by status

StatusCount
Went quiet3
Total3

Where it needs a new molecule

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
TargetRoute
SLC6A3 Sodium-dependent dopamine transporterRoute A
SLC6A2 Sodium-dependent noradrenaline transporterRoute A
SLC6A4 Sodium-dependent serotonin transporterRoute A

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

Where its trials are

  • Nutrition and metabolism: 3 trials led
  • Mental health: 1 trials led
  • Nervous system: 1 trials led